Citron Research published on Apellis Pharmaceuticals (NASDAQ: APLS — $5.57 billion), the makers of Syfovre – a drug that can help delay or prevent some cases of blindness. Citron published conversation excerpts from the American Academy of Ophthalmology conference that showed doctors raised concerns that Syfovre patients have too many adverse reactions. In addition, some doctors argued that Medicare should not pay roughly $25,000 per year for Syfovre in some cases because it “just slows the progression of retina lesions in an elderly patient.”
More ... latest change: 2026-02-08 2026-01-30 USD 22.58
last updated: